BioVersys AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Revenue	1.6	0.8	-	-
Other Revenue	3.02	2.38	1.21	1.14
Revenue	4.62	3.18	1.21	1.14
Revenue Growth	253.17%	161.75%	6.50%	-
Gross Profit	4.62	3.18	1.21	1.14
Selling, General & Admin	6.04	6.73	6.99	4.02
Research & Development	23.84	16.5	12.95	14.83
Other Operating Expenses	-0.09	-0.09	-	-
Operating Expenses	29.78	23.14	19.94	18.84
Operating Income	-25.16	-19.96	-18.72	-17.7
Interest Expense	-1.22	-1.08	-1.04	-0.7
Interest & Investment Income	0.04	0.05	0.5	0.48
Currency Exchange Gain (Loss)	0.32	-0.01	0.13	-0.16
Other Non Operating Income (Expenses)	-0.36	-0.81	0.42	-0.22
Pretax Income	-26.38	-21.81	-18.72	-18.3
Income Tax Expense	0.03	0.02	-	-
Net Income	-26.41	-21.83	-18.72	-18.3
Net Income to Common	-26.41	-21.83	-18.72	-18.3
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	6	6	3	3
Shares Outstanding (Diluted)	6	6	3	3
Shares Change	31.25%	68.49%	11.60%	-
EPS (Basic)	-4.51	-3.89	-5.62	-6.13
EPS (Diluted)	-4.51	-3.89	-5.62	-6.13
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-25.66	-22.16	-15.61	-11.7
Free Cash Flow Per Share	-4.39	-3.95	-4.68	-3.92
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-544.24%	-628.76%	-1543.45%	-1554.17%
Profit Margin	-571.27%	-687.56%	-1543.20%	-1606.76%
Free Cash Flow Margin	-555.07%	-698.02%	-1287.06%	-1027.57%
EBITDA	-25.04	-19.89	-18.66	-17.65
D&A For EBITDA	0.12	0.07	0.06	0.06
EBIT	-25.16	-19.96	-18.72	-17.7
Revenue as Reported	4.72	3.27	1.21	1.14